Biliary excretion of loracarbef and its clinical efficacy on surgical infections

The kinetic profile and clinical efficacy of loracarbef (LCBF), a new oral cephem, were investigated.LCBF was administered orally to 9 patients with cholelithiasis at doses of 200mg or 400mg.At 3-5 hours after administration before cholecystectomy, the gallbladder tissue concentration of LCBF was 0....

Full description

Saved in:
Bibliographic Details
Published inCHEMOTHERAPY Vol. 41; no. Supplement3; pp. 419 - 430
Main Author Tanimura, Hiroshi
Format Journal Article
LanguageEnglish
Japanese
Published Japanese Society of Chemotherapy 1993
Online AccessGet full text

Cover

Loading…
More Information
Summary:The kinetic profile and clinical efficacy of loracarbef (LCBF), a new oral cephem, were investigated.LCBF was administered orally to 9 patients with cholelithiasis at doses of 200mg or 400mg.At 3-5 hours after administration before cholecystectomy, the gallbladder tissue concentration of LCBF was 0.20-0.30μg/g at a single dose of 200mg or 400mg, and 0.05-1.25μg/g at doses of 200mg 3 times daily for 3 days.The concentrations in gallbladder bile at 3-5 hours after administration were 0.90-3.90μg/ml and 0.20-5.20μg/ml, respectively. LCBF was administered orally to 4 patients with an indwelling T-tube at a single dose of 200mg.The maximum bile concentration and recovery rate in bile were 3.29-6.55μg/ml and 0.13-0.17%.In 56 patients administered LCBF at doses of 200mg, 2 or 3 times daily for 2 to 15 days, the clinical efficacy was excellent in 3 cases, good in 43, fair in 9, and poor in 1, with the efficacy rate being 82%.No side effects were observed, except for one patient in whom GPT was elevated.
ISSN:0009-3165
1884-5894
DOI:10.11250/chemotherapy1953.41.Supplement3_419